GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026

GH Research (Nasdaq: GHRS) announced that the U.S. Food and Drug Administration has lifted the clinical hold on its IND for GH001, enabling U.S. subject enrollment and advancing plans for a global Phase 3 program targeted to start in 2026.

Rhea-AI Summary

GH Research (Nasdaq: GHRS) announced that the U.S. Food and Drug Administration has lifted the clinical hold on its IND for GH001, enabling U.S. subject enrollment and advancing plans for a global Phase 3 program targeted to start in 2026. The company said it will seek FDA alignment to replicate the Phase 2b design.

Key Phase 2b results cited: a placebo-adjusted -15.5 point MADRS reduction at Day 8 (p<0.0001), 57.5% remission at Day 8, 73% remission at six months with ~4 treatments on average, short psychoactive exposure (~11 minutes median), and no serious treatment-related adverse events.

Positive

• FDA lift of IND clinical hold enables U.S. enrollment
• Phase 2b primary endpoint: -15.5 point placebo-adjusted MADRS at Day 8 (p<0.0001)
• 57.5% remission at Day 8; 73% remission at 6 months with ~4 treatments
• Short psychoactive experience (~11 minutes) and no serious treatment-related adverse events

Negative

• Global Phase 3 start is targeted for 2026, pending FDA alignment and final program design
• Regulatory alignment across major jurisdictions is still required before global enrollment

Argus Jan 5 session

+16.77% close to close Open Argus

Details

News Market Reaction – GHRS

On Jan 5, the day this news came out, GHRS closed 16.77% above the previous close.

Data tracked by StockTitan Argus for the Jan 5 session.

Key Figures

MADRS reduction: -15.5 points Day 8 remission: 57.5% 6-month remission: 73% +5 more

MADRS reduction

-15.5 points

Placebo-adjusted change on Day 8 in Phase 2b trial

Day 8 remission

57.5%

TRD patients in GH001 Phase 2b trial

6-month remission

73%

Remission at 6 months with infrequent dosing

Average treatments

~4 treatments

Number of GH001 treatments over 6 months

Psychoactive duration

Median ~11 minutes

Duration of psychoactive experience with GH001

Discharge-ready rate

99%

Patients discharge-ready within 1 hour of dosing

P-value

p<0.0001

Primary endpoint in Phase 2b trial

Phase 3 timing

2026

Targeted initiation of global pivotal Phase 3 program

Historical Context

5 past events · Latest: Jan 02

5 events

1. Jan 02

   Regulatory update notice

   24h Move

   +4.3%

   Scheduled update on GH001 IND status and global Phase 3 plans.

2. Nov 06

   Earnings and clinical

   24h Move

   -1.3%

   Strong Phase 2b data, solid cash, and ongoing IND hold resolution.

3. Oct 09

   Conference presentations

   24h Move

   +0.1%

   ECNP congress presentations on long-term safety and efficacy data.

4. Aug 07

   Earnings and updates

   24h Move

   -0.4%

   Q2 results, strong cash, and progress on resolving GH001 IND hold.

5. Jul 23

   Program planning

   24h Move

   -14.7%

   Global pivotal program plans and impressive Phase 2b TRD results.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

clinical hold, investigational new drug application, phase 3, phase 2b, +3 more

7 terms

clinical hold regulatory

"the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its..."

A clinical hold is an order from a drug or medical-device regulator to stop or suspend a clinical trial or development activity because of safety concerns, inadequate study plans, or incomplete data. Think of it like a referee pausing a game until rules or safety issues are resolved; investors care because a hold can delay approval, increase costs, create uncertainty about a product’s future, and often affects a company’s valuation until the issues are addressed.

investigational new drug application regulatory

"...clinical hold on its Investigational New Drug Application (IND) for GH001."

An investigational new drug application is a formal request made to regulatory authorities to begin testing a new medication in humans. It is a critical step in the drug development process, as approval indicates the drug has passed initial safety checks and can be studied further. For investors, this signals that a potential new treatment is progressing through its early testing stages, which can impact the company's future growth prospects.

phase 3 medical

"...alignment on global Phase 3 program replicating Phase 2b design..."

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

phase 2b medical

"...global Phase 3 program replicating Phase 2b design..."

Phase 2b is a stage in the development of a new medicine or treatment where researchers test its effectiveness and safety in a larger group of people. This step helps determine whether the treatment works well enough to move forward and if it has manageable side effects, which is important for investors because successful results can lead to potential approval and market opportunity.

treatment-resistant depression medical

"...treatment option for TRD patients,” said Dr. Velichka Valcheva..."

A form of major depression that does not improve after a person has tried standard treatments such as common antidepressant medications and therapy; think of it as a stubborn problem that doesn’t respond to the usual fixes. It matters to investors because it represents a large unmet medical need and a higher-risk, higher-reward area for drug developers, with potential for premium pricing, regulatory scrutiny, and durable demand if an effective new therapy is approved.

madrs medical

"Primary endpoint met: -15.5 point placebo-adjusted MADRS reduction on Day 8..."

MADRS (Montgomery–Åsberg Depression Rating Scale) is a short, clinician‑completed questionnaire that assigns numbers to common symptoms of depression to produce a single score reflecting severity—think of it as a clinical “mood thermometer.” Investors watch MADRS results because drug trials often use changes in this score as the key measure of whether a treatment works; clear improvements or failures can strongly affect regulatory outcomes, market prospects and stock value.

psychoactive medical

"Short psychoactive experience (median of ~11 minutes)..."

Psychoactive describes any drug or chemical that changes how the brain works, affecting mood, perception, thinking or behavior — like turning up or down knobs on mental states. For investors, psychoactive properties matter because they drive product demand, safety concerns, and regulatory scrutiny: a compound that alters brain function can open medical markets but also trigger strict approvals, labeling, liability and legal restrictions that affect a company’s value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollment
• Company to seek FDA alignment on global Phase 3 program replicating Phase 2b design
• Phase 3 initiation targeted for 2026
  

DUBLIN, Jan. 05, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its Investigational New Drug Application (IND) for GH001.

This clearance enables U.S. subject enrollment and progresses the company toward alignment of its development across major jurisdictions.

“The FDA clearance is a major milestone and positions us to advance GH001 as a potential ultra-rapid and durable treatment option for TRD patients,” said Dr. Velichka Valcheva, Chief Executive Officer. “We continue to expect initiation of our global pivotal program in 2026. We look forward to meeting with the FDA to align on the design for the pivotal Phase 3 program.”

GH001 Phase 2b Profile Highlights from the Previously Reported Phase 2b trial (GH001-TRD-201):

• Primary endpoint met: -15.5 point placebo-adjusted MADRS reduction on Day 8 (p<0.0001)
• Ultra-rapid remission (57.5% of patients on Day 8); 73% remission at 6 months with infrequent dosing (~4 treatments on average)
• Short psychoactive experience (median of ~11 minutes)
• No required psychotherapy
• 99% of patients discharge-ready within 1 hour of dosing
• Favorable safety: well-tolerated, no serious treatment-related adverse events

Recent presentations at scientific conferences reinforce GH001's potential for integration into existing interventional psychiatry practices through its convenient administration profile.

Michael E. Thase, MD, Professor of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, said, “The large and rapid antidepressant effect observed with GH001 in the Phase 2b trial, combined with sustained remission through infrequent, short clinic visits, has the potential to be practice-changing for patients with treatment-resistant depression.”

About GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression. GH Research PLC's initial focus is on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD).

About GH001

Our lead product candidate, GH001, is formulated for mebufotenin administration via a proprietary inhalation approach. Based on the observed clinical activity in our Phase 2b GH001-TRD-201 trial, where the primary endpoint was met with a MADRS reduction from baseline of -15.5 points compared with placebo on Day 8 (p<0.0001), we believe that GH001 has the potential to change the way TRD is treated today.

Forward-Looking Statements

This press release contains statements that are, or may be deemed to be, forward-looking statements. All statements other than statements of historical fact included in this press release, including expectations with regard to initiating our global pivotal program, and the expected timing of such initiation, our future results of operations and financial position, business strategy, product candidates, research pipeline, ongoing and currently planned preclinical studies and clinical trials, regulatory submissions and approvals, research and development costs, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements appear in a number of places in this press release and include, but are not limited to, statements regarding our intent, belief or current expectations. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this document speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Investor Relations
Julie Ryan
GH Research PLC
investors@ghres.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did GH Research (GHRS) announce on January 5, 2026 about GH001?

The company announced the FDA lifted the IND clinical hold for GH001, allowing U.S. subject enrollment and aiming to start a global Phase 3 program in 2026.

What were the Phase 2b GH001 efficacy results GHRS reported?

Phase 2b showed a placebo-adjusted -15.5 point MADRS reduction at Day 8 (p<0.0001) with 57.5% remission at Day 8 and 73% remission at six months.

Does the FDA lift mean GH001 is approved for patients now (GHRS)?

No; the FDA lift clears the IND for U.S. clinical investigation and enrollment but is not marketing approval.

When does GHRS plan to begin the GH001 global pivotal Phase 3 program?

GH Research targets initiation of the global Phase 3 program in 2026, subject to FDA alignment on the trial design.

What safety profile did GH001 show in the Phase 2b trial reported by GHRS?

GH001 was described as well-tolerated with no serious treatment-related adverse events and most patients discharge-ready within 1 hour.

How might GH001 be administered in clinical practice according to GHRS data?

GHRS cited short clinic visits with a median ~11-minute psychoactive experience and infrequent dosing (~4 treatments on average) from Phase 2b.